Literature DB >> 21099130

Relationships between plasma fatty acid composition and coronary artery disease.

Hiroshige Itakura1, Mitsuhiro Yokoyama, Masunori Matsuzaki, Yasushi Saito, Hideki Origasa, Yuichi Ishikawa, Shinichi Oikawa, Jun Sasaki, Hitoshi Hishida, Toru Kita, Akira Kitabatake, Noriaki Nakaya, Toshiie Sakata, Kazuyuki Shimada, Kunio Shirato, Yuji Matsuzawa.   

Abstract

AIM: The Japan EPA Lipid Intervention Study (JELIS) was the first prospective randomized clinical trial to demonstrate prevention of coronary events by pure eicosapentaenoic acid (EPA). The aim of this study was to examine the relationships between various plasma fatty acid concentrations and the risk of coronary events in JELIS participants.
METHODS: In 15,534 participants, we calculated the hazard ratio for major coronary events (sudden cardiac death, fatal or nonfatal myocardial infarction, unstable angina pectoris, and angioplasty/stenting or coronary artery bypass grafting) relative to the on-treatment average level of plasma fatty acids with the Cox proportional hazard model.
RESULTS: As a result of EPA intervention, the plasma EPA concentration increased, but the docosahexaenoic acid (DHA) concentration did not. The other fatty acids measured decreased slightly. The higher plasma level of EPA (hazard ratio=0.83, p=0.049, in all participants and hazard ratio=0.71, p=0.018, in the EPA intervention group), but not of DHA, was inversely associated with the risk of major coronary events. The associations between other fatty acids and the risk of major coronary events were not significant. In all JELIS participants, the risk of major coronary events was significantly decreased (20%) in the group with high (150 µg/mL or more) on-treatment plasma EPA concentration compared with that in the low (less than 87 µg/mL) group.
CONCLUSION: The risk of coronary artery disease is influenced by variations in plasma fatty acid composition. Among n-3 polyunsaturated fatty acids, EPA and DHA exhibited differences in the correlation with the risk of major coronary events.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21099130     DOI: 10.5551/jat.5876

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  63 in total

1.  Combination of EPA with Carotenoids and Polyphenol Synergistically Attenuated the Transformation of Microglia to M1 Phenotype Via Inhibition of NF-κB.

Authors:  Nurit Hadad; Rachel Levy
Journal:  Neuromolecular Med       Date:  2017-08-04       Impact factor: 3.843

2.  Docosahexaenoic acid attenuates Western diet-induced hepatic fibrosis in Ldlr-/- mice by targeting the TGFβ-Smad3 pathway.

Authors:  Kelli A Lytle; Christopher M Depner; Carmen P Wong; Donald B Jump
Journal:  J Lipid Res       Date:  2015-08-27       Impact factor: 5.922

3.  A Comparative Overview of Prescription Omega-3 Fatty Acid Products.

Authors:  Matthew K Ito
Journal:  P T       Date:  2015-12

4.  Cyclodextrin-promoted energy transfer for broadly applicable small-molecule detection.

Authors:  Nicole Serio; Chitapom Chanthalyma; Lindsey Prignano; Mindy Levine
Journal:  Supramol Chem       Date:  2014       Impact factor: 1.688

Review 5.  n-3 Polyunsaturated Fatty Acids and Cardiovascular Disease: Principles, Practices, Pitfalls, and Promises - A Contemporary Review.

Authors:  Richard Kones; Scott Howell; Umme Rumana
Journal:  Med Princ Pract       Date:  2017-11-29       Impact factor: 1.927

6.  Peripheral Artery Disease Is Associated with a Deficiency of Erythrocyte Membrane n-3 Polyunsaturated Fatty Acids.

Authors:  Joel L Ramirez; Greg J Zahner; Kimberly A Spaulding; Sukaynah A Khetani; Nancy K Hills; Warren J Gasper; William S Harris; Beth E Cohen; S Marlene Grenon
Journal:  Lipids       Date:  2019-03-18       Impact factor: 1.880

7.  Whole-blood fatty acids and inflammation in European children: the IDEFICS Study.

Authors:  E M González-Gil; J Santabárbara; A Siani; W Ahrens; I Sioen; G Eiben; K Günther; L Iacoviello; D Molnar; P Risé; P Russo; M Tornaritis; T Veidebaum; C Galli; L A Moreno
Journal:  Eur J Clin Nutr       Date:  2016-01-13       Impact factor: 4.016

Review 8.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

9.  Does administration of eicosapentaenoic acid increase soluble thrombomodulin level in statin-treated patients with stable coronary artery disease?

Authors:  Shigemasa Tani; Rei Matsuo; Atsushi Hirayama
Journal:  Heart Vessels       Date:  2018-08-24       Impact factor: 2.037

Review 10.  Omega-3 fatty acid supplementation and cardiovascular disease.

Authors:  Donald B Jump; Christopher M Depner; Sasmita Tripathy
Journal:  J Lipid Res       Date:  2012-08-17       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.